Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
Two studies point to care gaps: missed kidney-protecting pills and blood pressure that runs too low or too high
-
The rest of today's sweep was background reading and unrelated topics, with no new kidney results to report.
Today brought no new treatment results, but two large real-world studies are worth a conversation with your care team. One suggests a sizable group of people who fit the guidelines for kidney-protecting SGLT2 pills are not taking them. The other found that in people with lower kidney filtering and no protein in the urine, blood pressure at either extreme tracked with more heart problems, which is a reminder that lower is not automatically better. Neither study tested a treatment, so treat both as questions to raise rather than reasons to change anything on your own.
The SGLT2i Treatment Gap in UK Primary Care: A Cross-Sectional RWE Study of Prescribing in Clinical Practice.
This UK study looked at family doctor records to count people who qualify for SGLT2 inhibitors but are not taking them. These are pills that protect the kidneys and heart in type 2 diabetes, chronic kidney disease, and heart failure. It found that use in UK primary care falls well short of what guidelines recommend, leaving a large untreated group. This is a snapshot of prescribing, not a test of the drugs, so it shows a gap in care rather than proving what causes it.
Blood pressure and cardiovascular risk in adults with non-proteinuric chronic kidney disease without diabetes.
This Japanese study followed 287,238 adults with reduced kidney filtering rate (eGFR under 60) who had no diabetes and little or no protein in their urine. It compared blood pressure levels against later heart attacks, strokes, and other heart problems. Both high blood pressure and unusually low blood pressure tracked with more heart events in this group. The study watched what happened in real life rather than assigning treatment, so it shows a link, not proof that the blood pressure itself caused the harm.
Dapagliflozin inhibits renal mesangial cell fibrosis by regulating HO-1/TGF-β1/Smad 2/3 axis.
This lab study tested dapagliflozin, an SGLT2 inhibitor already used in kidney disease, on kidney cells to work out how it reduces scarring. Scarring is the stiff tissue that builds up and gradually destroys filtering units. The researchers traced the effect to a specific chemical signaling chain inside the cell. This was done in cells, not in people, so it explains a possible mechanism behind a drug that already has human evidence.
Complement in Kidney Disease: Core Curriculum 2026
This is a teaching review about complement, a part of the immune system that fights infection but can also attack the kidney when it misfires. It explains that the US Food and Drug Administration has now approved complement-blocking drugs for five kidney diseases, including atypical hemolytic uremic syndrome and C3 glomerulopathy. It is a summary of what is already known, so there is no new data here. Useful as background if your diagnosis involves immune-driven kidney damage.
Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective.
This review lays out treatment goals for primary biliary cholangitis, a liver disease where the immune system attacks the small bile ducts. It is written for doctors in Australia. If untreated, the disease can scar the liver badly enough to need a transplant. The article reports no new results and is about the liver, not the kidneys.
Climate Change and Cardiovascular Complications of Diabetes.
This is a discussion piece about how heat waves, cold snaps, and air pollution raise heart and kidney risk for people with diabetes. It notes that people with diabetes handle heat poorly, dehydrate more easily, and often already have kidney or heart disease. There are no new results in it. The practical takeaway is that extreme weather is a real risk period if your kidneys are already struggling.
Enhanced Recovery After Surgery (ERAS) Versus Standard Postoperative Care in Elective Craniotomy for Brain Tumor Excision: A Comprehensive Review of Protocol Differences, Clinical Outcomes, and Implementation Challenges.
This review compares standard recovery care after brain tumor surgery with a structured program called Enhanced Recovery After Surgery. The newer approach cuts back on strong painkillers and gets patients eating and moving sooner. The authors gathered findings from other studies rather than running their own, so there are no new results here. It has nothing to do with kidney disease.
Mindfulness for Saudi Hemodialysis Patients
This is a registration for a study that is starting in Saudi Arabia, so there are no results yet. It plans to test whether guided mindfulness sessions during dialysis improve sleep, mood, and stress. The plan is 38 people with kidney failure on dialysis, split evenly between mindfulness and a comparison group, with 30-minute sessions three times a week for five weeks. A study this small can only hint at an effect, even once it reports.
Mild Cognitive Impairment Diagnosis and Care Algorithms and the Role of Digital Interventions: Expert Consensus.
A group of brain specialists in Asia agreed on how doctors should spot and treat mild memory and thinking problems, called mild cognitive impairment. They also discussed apps and other digital tools as possible treatments. This is expert opinion, not a study, so there are no results yet. It does not look at kidney disease.
Central nervous system lymphatic network: from the maintenance of brain homeostasis to emerging therapeutic perspectives in neurodegenerative diseases.
This review describes how the brain washes out waste through a drainage network, including the glymphatic system and lymph vessels in the brain's lining. Scientists once thought the brain had no such drainage at all. The authors suggest this system could one day be a target for treating brain diseases. It is a summary of other work, with no new results and no kidney data.
Evidence Summary of Pruritus Management in Patients With Atopic Dermatitis: Implications for Nursing Practice
This is a summary of the evidence on treating itching in people with eczema, written for nurses. It pulls together existing guidance rather than testing anything new. No abstract details were available, and no numbers are reported. Itching matters in kidney disease, but this article covers a skin condition instead.
Ayurveda in Contemporary Clinical Practice: Integrating Traditional Principles With Preventive, Metabolic, and Mind-Body Medicine.
This article argues that Ayurveda, a traditional Indian system of medicine, could fit into modern care for long-term and stress-related illness. The authors describe its approach to diet, behavior, and mind-body balance. They admit the evidence is scattered and the treatments studied vary a lot. No new results are reported, and kidney disease is not the subject.
Managing headache in primary care: choosing therapies that treat the whole patient.
This review gives family doctors a practical way to treat headaches while taking a patient's other long-term conditions into account. The goal is to use fewer drugs at once and avoid bad drug combinations. It draws on existing guidelines and past studies rather than reporting new findings. Kidney disease is not covered.
Gut Microbiota in Kidney Transplantation: Mechanistic Insights and Implications for Precision Immunosuppression.
This is a review of what is known about gut bacteria and kidney transplants, not a new study. It describes how the mix of gut bacteria shifts after a transplant, with less variety and more harmful strains, and how that may affect rejection, infection, and drug side effects. The authors suggest gut bacteria could one day help tailor anti-rejection medicine to the person. No results are reported here, and none of this is ready to change treatment.